S Bank Fund Management Ltd increased its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 14.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,000 shares of the medical instruments supplier’s stock after acquiring an additional 5,343 shares during the quarter. Becton, Dickinson and Company comprises 1.1% of S Bank Fund Management Ltd’s holdings, making the stock its 25th largest holding. S Bank Fund Management Ltd’s holdings in Becton, Dickinson and Company were worth $8,345,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP lifted its position in shares of Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after purchasing an additional 5,174,944 shares during the period. Vanguard Group Inc. raised its stake in Becton, Dickinson and Company by 13.0% during the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after buying an additional 4,223,149 shares during the last quarter. First Eagle Investment Management LLC lifted its holdings in Becton, Dickinson and Company by 13.8% in the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock valued at $1,870,653,000 after buying an additional 1,208,218 shares during the period. Veritas Asset Management LLP lifted its holdings in Becton, Dickinson and Company by 40.6% in the third quarter. Veritas Asset Management LLP now owns 2,954,898 shares of the medical instruments supplier’s stock valued at $553,068,000 after buying an additional 852,854 shares during the period. Finally, Rakuten Investment Management Inc. bought a new stake in Becton, Dickinson and Company during the third quarter valued at $152,931,000. 86.97% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 1,102 shares of company stock worth $198,909. Insiders own 0.40% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on Becton, Dickinson and Company
Becton, Dickinson and Company Stock Down 1.5%
BDX stock opened at $144.15 on Wednesday. The stock’s 50 day simple moving average is $159.87 and its 200 day simple moving average is $181.62. The company has a market cap of $41.04 billion, a P/E ratio of 23.52, a price-to-earnings-growth ratio of 10.43 and a beta of 0.22. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $4.49 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 12.52 earnings per share for the current fiscal year.
Becton, Dickinson and Company announced that its board has authorized a share buyback program on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
Becton, Dickinson and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 68.52%.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
